Minnelide reduces tumor burden in preclinical models of osteosarcoma

Sulagna Banerjee; Venugopal Thayanithy; Veena Sangwan; Tiffany N. Mackenzie; Ashok K Saluja; Subree Subramanian

doi:10.1016/j.canlet.2013.02.050

Minnelide reduces tumor burden in preclinical models of osteosarcoma

Sulagna Banerjee, Venugopal Thayanithy, Veena Sangwan, Tiffany N. Mackenzie, Ashok K Saluja, Subree Subramanian

Research output: Contribution to journal › Article › peer-review

48 Scopus citations

Abstract

Osteosarcoma is the most common bone cancer in children and adolescents with a 5-year survival rate of about 70%. In this study, we have evaluated the preclinical therapeutic efficacy of the novel synthetic drug, Minnelide, a prodrug of triptolide on osteosarcoma. Triptolide was effective in significantly inducing apoptosis in all osteosarcoma cell lines tested but had no significant effect on the human osteoblast cells. Notably, Minnelide treatment significantly reduced tumor burden and lung metastasis in the orthotopic and lung colonization models. Triptolide/Minnelide effectively downregulated the levels of pro-survival proteins such as heat shock proteins, cMYC, survivin and targets the NF-κB pathway.

Original language	English (US)
Pages (from-to)	412-420
Number of pages	9
Journal	Cancer Letters
Volume	335
Issue number	2
DOIs	https://doi.org/10.1016/j.canlet.2013.02.050
State	Published - Jul 28 2013

Bibliographical note

Funding Information:
This study was supported by grants R01CA124723 and R01CA170496 from the NIH (A.K.S.), by a Faculty Research and Development grant from the University of Minnesota Academic Health Center, by a translational research grant from the Masonic Cancer Center, University of Minnesota, by grants from the Wyckoff Rein in Sarcoma (S.S.).

Keywords

Heat shock proteins
Minnelide
NF-κB
Osteosarcoma
Triptolide

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1016/j.canlet.2013.02.050

OpenUrl availability

Full text

Cite this

@article{f949dffae84d43bc8b0864e20a0f34bf,

title = "Minnelide reduces tumor burden in preclinical models of osteosarcoma",

abstract = "Osteosarcoma is the most common bone cancer in children and adolescents with a 5-year survival rate of about 70%. In this study, we have evaluated the preclinical therapeutic efficacy of the novel synthetic drug, Minnelide, a prodrug of triptolide on osteosarcoma. Triptolide was effective in significantly inducing apoptosis in all osteosarcoma cell lines tested but had no significant effect on the human osteoblast cells. Notably, Minnelide treatment significantly reduced tumor burden and lung metastasis in the orthotopic and lung colonization models. Triptolide/Minnelide effectively downregulated the levels of pro-survival proteins such as heat shock proteins, cMYC, survivin and targets the NF-κB pathway.",

keywords = "Heat shock proteins, Minnelide, NF-κB, Osteosarcoma, Triptolide",

author = "Sulagna Banerjee and Venugopal Thayanithy and Veena Sangwan and Mackenzie, {Tiffany N.} and Saluja, {Ashok K} and Subree Subramanian",

note = "Funding Information: This study was supported by grants R01CA124723 and R01CA170496 from the NIH (A.K.S.), by a Faculty Research and Development grant from the University of Minnesota Academic Health Center, by a translational research grant from the Masonic Cancer Center, University of Minnesota, by grants from the Wyckoff Rein in Sarcoma (S.S.). ",

year = "2013",

month = jul,

day = "28",

doi = "10.1016/j.canlet.2013.02.050",

language = "English (US)",

volume = "335",

pages = "412--420",

journal = "Cancer Letters",

issn = "0304-3835",

publisher = "Elsevier Ireland Ltd",

number = "2",

}

TY - JOUR

T1 - Minnelide reduces tumor burden in preclinical models of osteosarcoma

AU - Banerjee, Sulagna

AU - Thayanithy, Venugopal

AU - Sangwan, Veena

AU - Mackenzie, Tiffany N.

AU - Saluja, Ashok K

AU - Subramanian, Subree

N1 - Funding Information: This study was supported by grants R01CA124723 and R01CA170496 from the NIH (A.K.S.), by a Faculty Research and Development grant from the University of Minnesota Academic Health Center, by a translational research grant from the Masonic Cancer Center, University of Minnesota, by grants from the Wyckoff Rein in Sarcoma (S.S.).

PY - 2013/7/28

Y1 - 2013/7/28

N2 - Osteosarcoma is the most common bone cancer in children and adolescents with a 5-year survival rate of about 70%. In this study, we have evaluated the preclinical therapeutic efficacy of the novel synthetic drug, Minnelide, a prodrug of triptolide on osteosarcoma. Triptolide was effective in significantly inducing apoptosis in all osteosarcoma cell lines tested but had no significant effect on the human osteoblast cells. Notably, Minnelide treatment significantly reduced tumor burden and lung metastasis in the orthotopic and lung colonization models. Triptolide/Minnelide effectively downregulated the levels of pro-survival proteins such as heat shock proteins, cMYC, survivin and targets the NF-κB pathway.

AB - Osteosarcoma is the most common bone cancer in children and adolescents with a 5-year survival rate of about 70%. In this study, we have evaluated the preclinical therapeutic efficacy of the novel synthetic drug, Minnelide, a prodrug of triptolide on osteosarcoma. Triptolide was effective in significantly inducing apoptosis in all osteosarcoma cell lines tested but had no significant effect on the human osteoblast cells. Notably, Minnelide treatment significantly reduced tumor burden and lung metastasis in the orthotopic and lung colonization models. Triptolide/Minnelide effectively downregulated the levels of pro-survival proteins such as heat shock proteins, cMYC, survivin and targets the NF-κB pathway.

KW - Heat shock proteins

KW - Minnelide

KW - NF-κB

KW - Osteosarcoma

KW - Triptolide

UR - http://www.scopus.com/inward/record.url?scp=84878221562&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878221562&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2013.02.050

DO - 10.1016/j.canlet.2013.02.050

M3 - Article

C2 - 23499892

AN - SCOPUS:84878221562

SN - 0304-3835

VL - 335

SP - 412

EP - 420

JO - Cancer Letters

JF - Cancer Letters

IS - 2

ER -

Minnelide reduces tumor burden in preclinical models of osteosarcoma

Abstract

Bibliographical note

Keywords

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this